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Background: Endocrine FGF21 and FGF19 target adipocytes and hepatocytes through betaKlotho (KLB) and FGFR
tyrosine kinases effecting glucose, lipid and energy metabolism. Both factors alleviate obesity and metabolic abnormalities
which are contributing factors to breast tumor progression. Genomic manipulation of hepatic FGFR4 has uncovered roles
of endocrine FGF signaling in both metabolic and cellular homeostasis. Here we determined whether systemic and
microenvironmental metabolic alterations caused by the FGFR4 deficiency affect tumorigenesis in breast where FGFR4 is
negligible. Breast tumors were induced in the bigenic mice with ablation of FGFR4 and overexpression of TGFα that
activates Her2 in the ductal and lobular epithelium surrounded by adipocytes. Mammary tumorigenesis and alterations in
systemic and breast microenvironmental metabolic parameters and regulatory pathways were analyzed.
Results: Ablation of FGFR4 had no effect on cellular homeostasis and Her2 activity of normal breast tissue. However, the
absence of FGFR4 reduced TGFα–driven breast tumor incidence and progression and improved host survival. Notable
increases in hepatic and serum FGF21, ileal FGF15/19, adiponectin and adipsin, and decreases in systemic Fetuin A, IGF-1,
IGFBP-1, RBP4 and TIMP1 were observed. The ablation affected adipogenesis and secretory function of adipocytes as well
as lipogenesis, glycolysis and energy homeostasis associated with the functions of mitochondria, ER and peroxisomes in
the breast and tumor foci. Treatment with a chemical inhibitor of NAMPT involved in the pathways inhibited the growth
and survival of breast tumor cells and tumor-initiating cell-containing spheres. The FGFR4 ablation also caused elevation
of inflammatory factors in the breast.
Conclusions: Although the primary role of FGFR4 in metabolism occurs in hepatocytes, its ablation results in a net
inhibitory effect on mammary tumor progression. We suggest that the tumor-delaying effect of FGFR4 deficiency may be
in large part due to elevated anti-obesogenic FGF21 that triggers tumor-suppressing signals from both peripheral and
breast adipocytes. The predominant changes in metabolic pathways suggested roles of metabolic effects from both
peripheral and breast adipocytes on metabolic reprogramming in breast epithelial cells that contribute to the suppression
of tumor progression. These results provide new insights into the contribution of systemic and microenvironmental
metabolic effects controlled by endocrine FGF signaling to breast carcinogenesis.
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Fibroblast growth factor receptors (FGFRs) are transmem-
brane receptor tyrosine kinases that sense extracellular en-
vironmental cues and trigger adaptive cellular responses
that include growth, survival and metabolic programming
[1,2]. They are encoded by four genes, namely FGFR1, 2, 3
and 4, with a number of splice isoforms. In association
with co-factor heparan sulfate (HS) proteoglycan motifs
and tissue-specific HS-binding and matrix-controlled FGF
ligands, these tyrosine kinases play paracrine and auto-
crine roles in embryonic development and adult tissue
homeostasis through control of cell proliferation, survival,
migration and differentiation [3-5]. Like epidermal growth
factor receptor (EGFR) and human epidermal growth fac-
tor receptor-2 (Her2), aberrations in the components of
the canonical FGF signaling pathway contribute to hyper-
plastic growth and tumorigenesis [6-9].
However, in the presence of tissue-specific transmem-
brane co-receptor Klotho (KL) and betaKlotho (KLB)
whose significant expression is limited to tissues in-
volved in systemic metabolism, and the KL/KLB-binding
endocrine FGFs (eFGFs) that include FGF19 (mouse
FGF15), 21 and 23, the same FGFR tyrosine kinases play
distinct roles in maintaining local and systemic homeo-
stasis of lipid, glucose, energy and mineral metabolism.
This shift occurs without an equal effect on mitogenic
and growth-promoting activities observed with canonical
FGFs [10-14]. The integration of tissue-specific KL/KLB
with the FGFR signaling complex appears to be the key
to this distinction [11,15,16]. KLB forms a binary com-
plex with FGFRs in metabolic tissues that confers high
affinity for the eFGFs [10,17], and in some cases, pre-
vents high affinity binding of canonical FGFs [15]. The
inter-organ cross-talking endocrine axis from hepatic
FGF21 to adipocyte FGFR1-KLB is a stress-responsive
pathway leading to the correction of deranged glucose,
lipid and energy metabolism that benefit the organism
during conditions of stress-induced pathologies such as
obesity, diabetes, fatty liver diseases, malignant transform-
ation and insults from toxins and infection [13,17-20].
Some of these pathologies are also risk factors for tumori-
genesis [21-24]. Ablation or overexpression of FGF21 ap-
pears to have no significant and direct effect on cell growth
and cellular structures in cells and tissues [14,25-27],
and its effects on metabolism are largely mediated dir-
ectly by FGFR1-KLB in adipocytes. The biological sig-
nificance of the distinction as well as the association
of the canonical cellular and non-canonical metabolic
signal pathways mediated by a same FGFR tyrosine kin-
ase in respect to growth and metabolism is presently un-
clear. They provide novel opportunities for the treatment
of obesity, type 2 diabetes, hypophosphatemia and di-
verse types of cancer where aberrant metabolism is a
complicating contributor.Compared to other FGFRs having a wider tissue-
expression pattern and high mitogenic potential, FGFR4
is highly expressed in the hepatocytes, and to a lesser ex-
tent or in a short time window in the muscle or during
muscle development [28-32]. When compared side by side
with other FGFRs under the same cellular condition, the
specific kinase activity of wild-type (WT) FGFR4 and its
activation of downstream signaling relays in the presence
of canonical FGFs is quantitatively less, although its intra-
cellular kinase domain through truncation or mutation
appears to be equally active [33-35]. However, in the
presence of resident KLB in hepatocytes, FGFR4 is highly
and specifically activated by ileum-derived postprandial
FGF19/15 and negatively regulates bile acids synthesis and
lipid metabolism with far-reaching indirect effects on en-
ergy metabolism [30,36,37]. The presence of KLB appears
to limit the functions of WT FGFR4 to metabolic regula-
tion rather than canonical cellular effects. Consistently, ab-
lation of KLB, FGF15 or FGFR4 causes hepatic deregulation
of bile acid synthesis without any apparent disruption of tis-
sue architecture and cellular homeostasis [30,37-39]. In
addition, mice deficient in FGFR4 exhibit mild systemic
alterations in metabolism that are related to obesity and
diabetes [36].
The significant expression of KLB is largely limited to
tissues involved in endocrine-controlled metabolic func-
tions that include mainly the adipose tissue and liver, and
does not overlap with the expression of FGFRs in other
tissues [10,17,32,40,41]. It is lost in the progression of
tumorigenesis such as hepatocarcinogenesis, and similar
to its homologue KL exhibits inhibitory effects on the
canonical growth-promoting functions of the FGFRs
[11,14-16,42]. The epithelial compartment of tissues other
than liver, adipose tissue and kidney appears to be devoid
of significant levels of KL/KLB. Some studies of FGFR4 in
mitogenicity and tumor development suggest that the role
of FGFR4 is insignificant or even suppressive in tumori-
genesis [11,43-46]. Some reports indicate variants or over-
expression of FGFR4 in tumors such as the lung and
pituitary where KLB is either not expressed at significant
levels in the parent tissues, or downregulated or lost
[47-49]. These inconsistencies may be due to variable de-
grees of canonical cell autonomous roles of overexpressed
or mutant FGFR4 in the absence of KLB, or indirect mi-
croenvironmental effects triggered by systemic metabolic
effects governed by the FGFR4-KLB partnership and
eFGFs. Although aberrant canonical FGF signaling is com-
monly associated with the abnormal cellular activities in
tumorigenesis, the KLB-mediated functional switch of
FGFRs to metabolic control provides a unique model to
dissect the canonical cellular and metabolic roles of FGF/
FGFR signaling in tumorigenesis.
In addition to hepatocytes, the mature adipocytes are
one of the major cell types that express KLB. In contrast
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FGFR isotype with KLB that mediates the metabolic re-
sponse of adipose tissue to eFGFs. Although adipocytes
comprise body fat depots as an independent tissue, they
are dispersed throughout the body among organs to dif-
ferent extents and increase with obesity. The breast tis-
sue is comprised of mostly fat interspersed with ductal
lobes that successively branch deeply into numerous
smaller lobular ducts until the formation of terminal
units that underlies basic breast function. It is ducts,
lobules and terminal units formed by the luminal epithe-
lium of cuboidal to columnar cells where breast cancers
are thought to mostly arise. Adipocytes surrounding lactif-
erous ducts, lobules and terminal units are thought to be
of major microenvironmental impact on the function and
fate of these units both in normal physiology and during
tumor progression. Metabolic abnormalities, particularly
those associated with obesity, have been shown as a major
risk factor for breast tumorigenesis. The interplay between
the adipose and ductal compartments underlies an excel-
lent model to study the effect of both local and systemic
changes in metabolism on mammary tumorigenesis.
In our previous reports, we showed that both FGF21
and FGF19 have profound beneficial effects in normalizing
local and systemic metabolic parameters through targeting
adipose tissues and liver, and are excellent candidates or
pathway targets for treatment of obesity, diabetes and
metabolic disorders [13,17,18,20]. In this report, we ex-
amined the development of spontaneous breast cancer
driven by overexpression of transforming growth factor
(TGF)α in the luminal epithelial cells of mouse breast
[8,9] in a genetic background of FGFR4 deficiency. We
found a negative impact of systemic and microenviron-
mental metabolic alterations resulting from this deficiency
that raises systemic FGF21 on the malignant transform-
ation of breast epithelial cells, which normally do not ex-
press FGFR4.
Methods
Mouse genetic manipulation and animal care
The MMTV-TGFα transgenic mouse strain (referred to
as Tg thereafter), FVB.Cg-Tg(MMTVTGFΑ)254Rjc/J,
was obtained from The Jackson Laboratory (Bar Harbor,
ME, USA), and back-crossed to C57BL/6 J for more than
five generations. The whole-body FGFR4 knockout
C57BL/6 J mice (FGFR4−/−, referred to as KO thereafter)
was established as previously described. The FGFR4−/−:
MMTV-TGFα bigenic mice (referred to as KO-Tg there-
after) were generated by crossing C57BL/6 J Tg mice
with the KO mice. Female animals with appropriate ge-
notypes were randomized according to age and/or body
weight into control and treatment/study groups.
All mice were housed in the Program of Animal Re-
sources in the Institute of Biosciences and Technology,Texas A&M Health Science Center, and were main-
tained in accordance with the principles and procedure
of the Guide for the Care and Use of Laboratory Ani-
mals. All experimental procedures were approved by the
Institute of Biosciences and Technology Institutional
Animal Care and Use Committee (IBT IACUC) with
protocols #08058 entitled The Impact of Obesity and
Obesity Treatment in Cancer and #10022 entitled BetaK-
lotho-FGFR in the liver.
Genotyping
Mouse tail DNA was used for genotyping. Primer pair 5′-
AGTTCTGCTTCCATGGAACC and 5′-TGATGATAAG
GACAGCCAGG was used for TGFα transgenic mice. Pri-
mer pair 5′-ACCAACACTGGAGCCTGGT and 5′-TGG
CAGACTTCTGCTCCTT was used for WT FGFR4 mice,
and the latter primer was used together with a primer 5′-
ATCGCCTTCTATCGCCTTGACGA from the Neo gene
for the FGFR4−/− mice [39].
Tumor and tissue sample harvesting
Mice were sacrificed, breast tumors and breasts were re-
moved, and a complete autopsy for all breasts and tu-
mors in each mouse was performed. The samples were
evaluated by a pathologist in a blinded manner on the
basis of H&E-stained sections, and the breast alterations
were classified as hyperplasia, adenoma and duct carcin-
oma. The autopsy samples of lymph node, lung, liver
and brain were evaluated histopathologically for the
presence of metastases.
Tissue processing and immunohistochemistry
Breasts and breast tumors were removed from mice and
fixed in 4% paraformaldehyde (PFA)-PBS for 4 h. Fixed
tissues were processed for ethanol dehydration and par-
affin embedding as described [50]. Paraffin-embedded
tissue blocks were serially sectioned and slide-mounted.
The sections (5 μm) were deparaffinized and rehydrated
before staining with H&E reagents, or primary and sec-
ondary antibodies for immunohistochemistry (IHC)
as indicated [50]. Ki67 and 5-bromo-2′-deoxyuridine
(BrdU) staining for mitotic index were done according to
the manufacturer’s protocol (Sigma-Aldrich, St Louis,
MO, USA). The section was then counterstained with
hematoxylin and mounted with 1,1′-(1,4-phenylenebis
(methylene))bis-pyridiniudibromide (DPX) media. The
slides were analyzed by a pathologist and photographed
digitally by light microscopy.
Breast tumor incidence
The tumor incidence in the age-matched KO-Tg and
Tg mice was defined as the percentage of mice with
tumor(s). The palpable breast tumor foci found in
each mouse in both groups were further confirmed by
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scope, and the incidence rate of breast tumor was
calculated as percentage of the whole population in
each group monthly (Tg, 218 mice; KO-Tg, 206 mice).
Tumor multiplicity defined as number of breasts having
tumor per mouse was also recorded monthly for the
duration of the experiments. Tumor size was mea-
sured with a gauge. Mice were sacrificed if the tumor load
was excessive.
Mouse survival analyses
The life span of mice was the duration between the date
of birth and the date of death or mandatory sacrifice due
to tumor burden or illness. The curves for the rates of
overall and breast tumor-specific survival in both the
FGFR4-deficient (216 mice) and WT mice (245 mice)
with TGFα overexpression were constructed using the
Kaplan-Meier method with the log-rank test. Overall
survival was expressed as the number of months to the
date of death or sacrifice in both groups suffering from
illnesses as a result of TGFα overexpression and/or
FGFR4 deficit. The rate of breast tumor-specific survival
was defined as the number of months from diagnosis
of specifically the breast cancer to the date of death or
sacrifice. Differences in the frequencies of the basic char-
acteristics, clinical parameters, and subtypes were statisti-
cally analyzed using either the chi-square test or Fisher’s
exact test in cases when the expected values of any of the
tumors were <5.
Quantitative gene expression analyses
Excised breasts, breast tumor tissues, ileum and liver tis-
sues were snap-frozen in liquid nitrogen and stored
at −80°C until use. Total RNA was isolated using Ultraspec
RNA Isolation reagents (Biotecx Laboratories, Houston,
TX, USA). Equal amounts of total RNA from five to twelve
mice were either pooled or individually used, and then
1 μg was subjected to the reverse transcription with
random hexamer primer. Relative gene expression was
measured by real-time PCR, and data presentation and
statistical analyses were as described [17]. The pathway-
focused quantitative PCR array analyses of adipogenesis,
fatty acid metabolism, glucose metabolism and mitochon-
drial energy metabolism were performed according to the
manufacturer’ s protocols (SABiosciences-Qiagen, Valencia,
CA, USA), in each of which 84 predominant genes were
probed. Quantitative PCR was then used to confirm the
significantly altered mouse genes revealed in the array ana-
lyses. The expression levels were normalized to the β-actin
in each tissue, and were then expressed as changes re-
lated to those of the WT samples, which is assigned as
an arbitrary unit of 1. In addition, primer pair CGAT
GAGCTTGGAGAAATCA GTAGTCCATGGGCACTGT
TG was used for quantitation of Acly expression, GAACTTGTGCAGGTTGGATG and TGCATCTCCTTTCTCT
CCCT for adiponectin, CCACGCCAACTGTACCTATG
and ATCCACTGCCATTGAACGTA for EGFR1 (Her1 or
ErbB1), TCATCATTGCAACTGTGGTG and ATCTTCT
GTCGCCTTCGTTT for Her2 (ErbB2), GGCAAGATA
TACGGGCTGAT and GATGGTGCTTCATGGATCTG
for FGF15 (human FGF19), TTCAAATCCTGGGTGT
CAAA and CAGCAGCAGTTCTCTGAAGC for FGF21,
CTGAAGGAGGGTCATCGAAT and GTCCAGGTCTT
CCACCAACT for FGFR1, CACCACGGACAAAGAGA
TTG and TGTCAACCATGCAGAGTGAA for FGFR2,
AGATGCTGAAAGATGATGCG and ATGATGTTCTT
GTGCTTGCC for FGFR3, GCTCGGAGGTAGAGGTC
TTG and TGTTGTCCACGTGAGGTCTT for FGFR4, 5′-
GGCGAATTATAGTGCTGCAA and 5′-TGGTGTTG
CAATGAATGTTG for HSD17B4, 5′-CAGAGAAGGAG
GAGGTGAGG and 5′-CAGCACCTGCCTTAAGTTGA
for KLB, AGCTCTTCCTCATGGCTGTT and TTTGCC
AGTTCCTCCAGATA for IFNγ, TGTATCTCTCTGAAG
GACTCT and TGTGCAATGGCAATTCTGATT for IL6,
AATGTCTCCTTCGGTTCTGG and CAAGGCCATTG
GTTACAACA for nicotinamide phosphoribosyltransferase
(NAMPT), and CCTCCCTCTCATCAGTTCTAT and
CAGAGAGGAGGTTGACTTTCT for TNFα.
Immunoblotting and antibody array analyses
Frozen tissues were ground with mortar and pestle in li-
quid nitrogen, and the powdered materials were further
lysed either in 1 × SDS sample buffer for direct SDS-PAGE
separation and western blotting analyses, or in modified
cold radioimmunoprecipitation assay (RIPA) buffer for
antibody array analyses for mouse phospho-RTK accord-
ing to the manufacturer’ s protocol (R&D Systems, Inc.
Minneapolis, MN, USA). Protein concentration was deter-
mined by the Bradford protein assay (Bio-Rad, Hercules,
CA, USA) using bovine gamma globulin as the standard.
Serum collection and adipokine array analyses
Fresh blood was collected from bleeding through the
jugular vein, and after coagulation for 1 h at room
temperature serum was prepared by low-speed centrifu-
gation for 20 minutes. Hemolysis was not observed. The
sera obtained from blood samples were frozen after pro-
tein concentration was determined at −80°C until further
analysis. Equal amounts of sera according to protein
content were used for antibody array analyses for mouse
adipokines (R&D Systems, Inc.).
Fecal bile acids analysis
The collection of feces and extraction of bile acids from
feces have been described previously [30]. Quantitative
analyses of bile acids content were done by the enzyme
cycling method according to the Bile Acid Assay proto-
col (Diazyme Laboratories, Poway, CA, USA).
Figure 1 Fibroblast growth factor receptor (FGFR)4 deficiency
reduced mammary tumor incidence. The age-matched C57BL/6
J KO-Tg and Tg mice as indicated were examined for the presence
of palpable breast tumor foci that were further confirmed by
pathological examination on tissue sections under microscope. The
incidence rate of breast tumor was determined monthly as the
percentage of the whole population in each group (Tg, 218 mice;
KO-Tg, 206 mice). Experimental data from three cohorts are
expressed as mean ± SD; P <0.05. KO, FGFR4 knockout; Tg, MMTV-TGFα
transgenic mouse.
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After an overnight fast, body weight and age-matched
KO-Tg and Tg mice were randomized for glucose ad-
ministration at 1 g/kg body weight by gastric gavage.
Blood samples were collected, and the glucose level was
determined by glucometer at 0, 15, 30, 60 and 120 mi-
nutes after delivery of the glucose load.
Intraperitoneal insulin tolerance test (IPITT)
After 6-h fasting, mice were randomized for intraperito-
neal injection of insulin at 0.75 units/kg body weight.
Blood samples were collected for measurement of the
glucose level at 0, 15, 30, 45, 60, 90 and 120 minutes
after the insulin injection.
Body weight monitoring
Body weights of KO-Tg and Tg groups with 216 and 245
mice, respectively, were recorded every week after birth
for the duration of the experiments.
Breast tumor cell growth and tumor-sphere formation
Solid breast tumor nodes were freshly isolated from
mice, minced into pieces smaller than 1 mm in diameter
in serum-free DMEM-F12 medium, and further dissoci-
ated with 0.1 mg/ml each of collagenase and hyaluroni-
dase for 2 h at 37°C. The digested mixtures were passed
through a 40-μm cell-strainer mesh tube (BD Biosci-
ences, San Jose, CA, USA). The separated single cells in
infiltrates were collected by centrifugation and cultured
for one day in medium supplemented with 10 ng/ml
FGF2, 10 ng/ml EGF, 1 μg/ml insulin and 0.5% BSA.
Adherent cells were dissociated from the culture dish
by pronase, and reseeded at 3 × 103 cells/well into 6-
well Ultra Low Cluster Plates (Corning Inc. Corning,
NY, USA). After 3 days, a NAMPT inhibitor FK866
or cytotoxic Triptolide (Cayman Chemical, Ann Arbor,
MI, USA) at 5 μM was added. Development of tumor
cell spheres was counted after 2 weeks. Adherent cells
at 1.5 × 104 were also treated with these inhibitors
for 5 days in adherent cell culture plates, and the num-
ber of cells that survived after 6 days was counted. In-
dependent experiments were performed at least three
times.
Human breast cancer tissue microarray
Tissue microarrays of 48 cases of breast cancer, with
36 matched metastatic breast cancer and 12 normal
tissue (US Biomax Inc. Rockville, MD, USA) (http://
www.biomax.us/tissue-arrays/Breast/BRM961) were as-
sessed by IHC for expression of NAMPT with an anti-
NAMPT (PBEF) antibody (Santa Cruz Biotechnology,
Dallas, TX, USA) as described [50]. The sections were
counterstained with hematoxylin and examined by a
pathologist.Statistical analysis
Kaplan-Meier survival curves were made using Graph-
Pad Prism 4 (GraphPad Software, San Diego, CA, USA)
and analyzed using the Mantel-Cox log-rank test. Exper-
iments were reproduced for three times independently
with triplicates within each experiment. A representative
of three or more experiments may be shown in micro-
graphs. Where indicated, the mean and SD is shown
with statistic analyses by the Student unpaired t-test be-
tween two groups, or one-way analysis of variance
(ANOVA) between multiple groups. Statistical signifi-
cance is denoted as follows: *P <0.05; **P <0.01.
Results
The FGFR4 deficiency reduces breast tumor incidence
Consistent with a previous report [39], germline ablation
of FGFR4 caused no detectable changes on the tissue
architecture or cellular relationships in the mammary fat
tissue component, muscular component and lactiferous
ducts, lobules or terminal units. Lactation, birth rate and
survival of offspring were also similar to WT female
mice (not shown). However, upon MMTV-promoter-
driven TGFα overexpression, both KO-Tg and Tg female
mice started to develop palpable breast tumors that dis-
rupted the normal breast tissue structure 4 to 6 months
after birth (Figure 1). There was no apparent phenotypic
effect on male mice in either genetic group. Breast tu-
mors were 70% cystic- and 30% solid-type. Most breast
tumors were localized in the upper trunk of the body
and more than 85% of tumors occurred in a single breast
site. Quantitative analyses of palpable breast tumors
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both age-matched 218 Tg and 206 KO-Tg mice revealed
that the Tg mice consistently had higher incidence of tu-
mors and more rapid tumor progression than the KO-Tg
mice (Figure 1). At 8 to 9 months, tumor incidence in
Tg mice was 23 to 28% and the incidence in KO-Tg mice
was about 5 to 8%. Tumor incidence reached a plateau of
about 55 to 60% in the Tg group, which was only 17 to
22% in the KO-Tg group at 10 to 12 months (Figure 1).
Toward the end of the observation period mandated by
the animal protocol and limits on tumor burden, only mice
from the KO-Tg group remained as a result of reduced
tumor incidence and delayed tumor progression.
Foot and toe cysts were observed in both genotypes.
Some mice with breast tumors had cysts, but not all
mice with foot and toe cysts had palpable breast tu-
mors. There was also spontaneous sebaceous gland
hyperplasia in both groups evidenced as multiple raised
white plaques or nodules on the abdomen. In contrast
to breast tumors, the incidence of foot and toe cysts as
well as the sebaceous gland hyperplasia was elevated in
the KO-Tg mice relative to Tg mice. Greater than 90%
incidence of foot and toe cysts and 24% incidence of se-
baceous gland hyperplasia were observed in the KO-Tg
mice compared to only 12 and 11%, respectively, in the
Tg mice (not shown).
The FGFR4 deficiency increases survival rate
Breast cancer host survival rates were determined by the
end-stage dictated by the extent of cancer burden that
required sacrifice, or by their natural death as a result of
mortal breast tumor burden and/or illnesses, such as
foot and toe cysts and sebaceous gland hyperplasia. The
overall survival rate of both genetic groups was defined
as total months to sacrifice or natural death as a result
of TGFα overexpression and/or FGFR4 deficit. The rate
of breast tumor-specific survival was defined as the
number of months until sacrifice or death after specific
diagnosis of breast cancer. We analyzed 245 WT mice
and 216 FGFR4-deficient mice, both expressing MMTV
promoter-driven TGFα, using the Kaplan-Meier method.
The overall survival (Figure 2A) and breast tumor-specific
survival (Figure 2B) rates were both higher in the FGFR4-
deficient TGFα transgenic mice than the FGFR4-WT
TGFα transgenic mice.
The FGFR4 deficiency delays pathological progression of
breast cancer
Age-matched tumor samples were collected from both
groups. Serial sections of early breast tumor tissues at 4
to 8 months were graded for pathological stages in
breast tumor development from mammary gland hyper-
plasia through ductal carcinomas in situ (DCIS) and
lobular carcinomas in situ (LCIS) to invasive carcinoma.The pathologist was blinded to the genotypes of the tis-
sue samples. Most of the breast or palpable tumor nodes
from the KO-Tg group at 6 months were found predom-
inantly in lower grades of the usual duct hyperplasia
(UDH) (57%) (Figure 3A) and high-grade UDH (hUDH)
(20%), whereas LCIS (Figure 3B) and DCIS (Figure 3C)
were only 10 and 13%, respectively (Table 1). In contrast,
tumors from the Tg group at the same age exhibited a
higher grade of anatomopathological features. With a
significant decrease in the grade of UDH to 16%, the
hUDH (Figure 3E), LCIS and DCIS were significantly in-
creased to 26, 23 and 28%, respectively, with the appear-
ance of invasive lobular carcinoma (Figure 3F) and
invasive ductal carcinoma (Figure 3G) (Table 1). These
cellular/tissue abnormalities were in contrast to breasts
from WT mice that exhibited typical duct and lobular
structures with limited cellularity surrounded by adipo-
cytes and stromal components (Figures 3D, 4A). Most
tumors in both groups resembled the highly expanded
tubular, adenoid cystic or papillary types shown in
Figures 3A-C, 3E and 4B-C. Adenomyoepithelioma,
myofibroblastic sarcoma, basal-like carcinoma, neuroen-
docrine carcinoma, glycogen-rich clear-cell carcinoma,
phyllodes tumors, breast lymphatic invasion and liposar-
coma appeared sporadically (data not shown). After
8 months, most of the palpable breast cancer nodes in
Tg mice were either cystic or solid with over 65% con-
taining poorly differentiated and highly invasive duct
and lobular carcinomas or solid sheets of tumors of no
specific type (Figure 3F, 3G, 3H). Among them, 34% of
breast tumors exhibited highly disorganized infiltrating
tumor cells indicated by easily identifiable muscle inva-
sion (Figure 3H) (Table 1). In contrast, about 25% of the
KO-Tg mice developed poorly differentiated carcinomas,
and among them only 12% developed invasive carcin-
oma. No detectable metastasis in distal tissues or organs
was evident in either genotype. The end-stage breast
cancer samples harvested after mandatory sacrifice irre-
spective of the age exhibited no significant differences in
tumor pathology despite the reduced tumor incidence
and higher survival rate in the KO-Tg group. These re-
sults indicate that the absence of FGFR4 exerts its effect
during early breast tumor progression.
Consistent with the delay in breast cancer development
indicated by the pathological analyses, the mitotic index
indicated by IHC staining for Ki67 was reduced by 15% in
6-month breast tumor foci from the KO-Tg compared to
age-matched Tg mice (Figure 4B, 4C, 4D). As expected,
breast ducts and lobular units in samples from normal WT
mice exhibited few mitotic figures (Figure 4A, 4D). There
was also a similar 22% reduction in the BrdU staining in
the KO-Tg breast tumors compared to the Tg tumors (data
not shown). This further suggests an effect of FGFR4 defi-
ciency on early development of breast tumorigenesis.
Figure 2 Fibroblast growth factor receptor (FGFR)4 deficiency increased the survival of mice with breast tumor. Life spans were scored
in days as described in Methods. We monitored 245 Tg and 216 KO-Tg mice. The rates of overall (A) and post breast tumor diagnosis survival
(B) in both the FGFR4-deficient and WT mice with TGFα overexpression were determined by Kaplan-Meier analysis. Tg, MMTV-TGFα transgenic;
KO, FGFR4 knockout; WT, wild-type; TGFα, transforming growth factor alpha.
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effect on Her2 activation
We investigated mechanisms by which the FGFR4 deficit
led to the delay in breast cancer progression driven by the
overexpression of TGFα. Quantitative PCR analyses at the
mRNA levels for members of the EGFR family, Her1 to 4,
and FGFR family, FGFR1 to 4, revealed that the FGFR1,
Her1 and Her2 are the major isotypes of the FGFR andFigure 3 Fibroblast growth factor receptor (FGFR)4 deficiency delaye
lesions were identified in the breast tumor tissue sections from the MMTV-
groups and compared at a similar age of 6 months. Most of the breasts or
grades including the usual duct hyperplasia (UDH) (A), lobular carcinoma in si
age they were in higher grade of UDH (E), invasive lobular carcinoma (F) and
breasts from wild-type mice with the typical duct and lobular structures surro
and 288 samples or sections from the Tg and KO-Tg groups, respectively.EGFR family in the breast, respectively (Figure 5A). They
were increased to a low but statistically significant extent
in the breast tumor tissues in both KO-Tg and Tg groups
(Figure 5A). After normalization to β-actin, the expression
level of FGFR4 was the lowest or negligible, which was
about 140-fold lower than FGFR1 and about 17-fold less
than Her2 (Figure 5A). Both expression levels for FGFR2
and FGFR3 were also low but considerably exceeded thatd pathological development of breast tumors. Mammary gland
TGFα transgenic (Tg) and FGFR4−/−: MMTV-TGFα bigenic (KO-Tg) mouse
palpable tumor nodes from the KO-Tg group were found in lower
tu (LCIS) (B), and duct carcinoma in situ (DCIS) (C); while at a comparable
invasive duct carcinoma (G, H) in the Tg group. This is in contrast to
unded by adipocytes (D). Micrographs are representative of about 312
Table 1 Effects of FGFR4 deficiency on the pathological development of mammary tumors*
Age (months) Genotype UDH hUDH DCIS LCIS Undiff STS IDC ILC
6 KO- Tg 57 20 10 13 0 0 0
6 Tg 14 26 23 28 2 2 5
8 KO-Tg 11 27 16 21 13 5 7
8 Tg 6 10 8 11 31 15 19
*Tissue sections from 24 mice each for the FGFR4−/−: MMTV-TGFα bigenic (KO-Tg) and MMTV-TGFα transgenic (Tg) mouse groups at 6 and 8 months were examined
for the anatomopathological grades. The predominant pathological category for each section was recorded and the percentage score of each pathological category
in total sections analyzed was reported. Three sections for each sample were analyzed. UDH, usual duct hyperplasia; DCIS, ductal carcinomas in situ; LCIS, lobular
carcinomas in situ; hUDH, high-grade UDH; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Undiff STS, undifferentiated solid tumor sheet.
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of FGFR4 was 152-fold lower in breast tissue than the
liver, which is the only known tissue expressing functional
FGFR4 at a high level (Figure 5B). In addition, the expres-
sion of FGFR4 in the white adipose tissue (WAT) is also
negligible as compared to FGFR1 and KLB. These results
indicate that FGFR4 expression and therefore, its tyrosine
kinase activity, is likely insignificant within the cells of the
breasts and breast tumors.
TGFα, whose overexpression drives the breast tumors
in the mouse model studied here, is closely related to
EGF and an activating ligand for the proto-oncogene
Her2, also called Neu or ErbB-2, a member of the EGFR
family [51]. Phospho-tyrosine (active) kinase antibody array
analyses on breast and breast tumor tissues revealed thatFigure 4 Fibroblast growth factor receptor (FGFR)4 deficiency reduce
by immunohistochemical analyses of tissue sections from wild-type (WT) (A), F
mice (C) (n = 12 for each group) at 6 months as indicated, and quantified by c
random fields under the light microscope (D). Data are expressed as percentagthe activities of both EGFR (Her1) and Her2 were en-
hanced about 7.5-fold in the TGFα transgenic mice relative
to the non-transgenic controls (Figure 5C, 5D). However,
there was no apparent difference between the FGFR4−/−
and FGFR4+/+ groups together with TGFα transgene or
without it. The expression and activity of Her3 and Her4
were also negligible (Figure 5A). Thus the FGFR4 defi-
ciency has no direct and significant effect on tumor-
associated levels of the EGFR family members Her1 and 2,
two of which likely underlie the TGFα-driven tumors.
KLB, the co-receptor required for the metabolic activ-
ities of FGFR4, is expressed in the breast at a level of
about 3- to 5-fold less than visceral WAT and the liver
(Figure 5B). KLB is localized in the stromal fraction, most
of which is fat-like tissue, but not the luminal epithelials mitoses in breast tumor foci. The expression of Ki67 were assessed
GFR4−/−: MMTV-TGFα bigenic (KO-Tg) (B) and MMTV-TGFα transgenic (Tg)
ounting the positive dots in the populations of tumor cells in different
e and means ± SD; *P <0.05.
Figure 5 Insignificant effects of fibroblast growth factor receptor (FGFR)4 deficiency on human epidermal growth factor receptor (Her)
and FGFR expression, Her2 activation and cellularity of the mouse breasts. (A) The expression of FGFR1/2/3, Her1/2, betaKlotho (KLB),
estrogen receptor (ER)α and adiponectin receptor (AdipoR)1 in the breasts and tumors from the wild-type (WT), FGFR4 knockout (KO), MMTV-TGFα
transgenic (Tg) and FGFR4−/−: MMTV-TGFα bigenic (KO-Tg) mice at 6 months was analyzed by quantitative PCR (see Methods). mRNA levels
were normalized to β-actin and expressed as fold change relative to that of FGFR1 in WT breasts, which was assigned an arbitrary unit of 100.
(B) Comparative expression of FGFR1, FGFR4 and KLB in the white adipose tissue (WAT), liver and breast were analyzed by quantitative PCR, and
expressed as changes relative to β-actin levels in the respective tissues. Indicated data are means ± SD, P <0.05 (n = 6/group). (C) Antibody array for
a panel of activated kinases was done (see Methods) using tissue extracts from six mouse breasts in each of the WT, KO, Tg and KO-Tg groups.
Representative micrographs of the dot blot strips for the four members of the Her family are shown. PC, positive antibody control. (D) Quantitative
densitometric analyses of phosphorylated Her1 (pHer1) and Her2 from (C) shown as means ± SD, P <0.05 (n = 3). (E) Representative section of the
mammary tissues from the KO mice at 6 months showing no change in the cellularity and structure of the mammary tissue.
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ing). It is significantly reduced in breasts with developing
tumor nodes due to loss of adipose tissue, and is not
present in the tumor foci (Figure 5A, Additional file 1:
Figure S1B). In contrast, FGFR1, the partner of KLB acti-
vated by FGF21, is widely expressed in adipocytes, normal
luminal epithelium and tumor cells (Additional file 1:
Figure S1C, S1D, orange staining). The expression of es-
trogen receptor alpha (ERα) was also reduced during
breast tumorigenesis driven by TGFα (Figure 5A).
Alterations of systemic metabolic factors
Consistent with a negligible level of expression and lack of
significant effect on Her1/2 activity and with previous
reports, there was no significant change in the breast
tissue architecture and function due to the FGFR4 defi-
ciency in the WT mice (Figures 5E, 3D and 4A) [30,39].
We thus turned to the systemic metabolic activities of
FGFR4 as a potential source of the negative impact on
breast tumor progression. Elevation of bile acids through
abrogation of FGFR4-KLB in the liver is the early and
most well-documented effect of a genome-wide deficiencyin FGFR4 [30]. Analysis of fecal content of bile acids in-
deed revealed an elevation in the KO-Tg mice, similar to
the FGFR4−/− -alone mice (Additional file 1: Figure S2A).
Previously reported changes in serum glucose, lipids and
insulin sensitivity caused by FGFR4 deficiency were also
recapitulated in the KO-Tg mice (Additional file 1: Figure
S2B, S2C, S2D). FGFR4 deficiency had little effect on body
weight (Additional file 1: Figure S2E).
Examination of circulating adipokines by antibody array
in age-matched KO-Tg and Tg mice revealed a 5-fold
increase in the systemic level of endocrine FGF21 in
the FGFR4−/− mice relative to that in the FGFR4+/+ mice
(Figure 6A and inset). Among a panel of other adipokines
analyzed, adiponectin levels were increased more than 2-
fold, and Fetuin A, insulin-like growth factor (IGF)-1, IGF
binding protein (IGFBP)-1, retinol binding protein (RBP)4
and tissue inhibitor of metalloproteinase (TIMP)1 were
decreased 2.5-, 25.0-, 2.5-, 3.0-, and 12-fold, respectively,
in the FGFR4−/− mice bearing breast tumors (Figure 6A
and inset). These significant changes were further con-
firmed by quantitative PCR. FGF21 expression in the liver,
the predominant production site of endocrine FGF21, was
Figure 6 Effects of fibroblast growth factor receptor (FGFR)4 deficiency on systemic adipokine levels in tumor-bearing mice. (A)
Antibody-based array analyses. The panel of adipokines as indicated was measured simultaneously in sera from the MMTV-TGFα transgenic (Tg)
and FGFR4−/−: MMTV-TGFα bigenic (KO-Tg) mice (n = 8 for each group) at 6 months. Changes of adipokine levels were expressed as log of the
densitometric ratio of KO-Tg to Tg. Data are means ± SD; P <0.05. (B-D) Changes in expression of liver FGF21, ileal FGF15 and breast adiponectin
(ADIPOQ) in the wild-type (WT), FGFR4 knockout (KO), Tg and KO-Tg mice at 6 months were determined by quantitative PCR. Results were
normalized to the β-actin levels in the respective samples and then expressed as fold change relative to that of WT, which is assigned as an
arbitrary unit of 1 or 100. Data are means ± SD, *P <0.05 (n = 6 for each group).
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background (Figure 6B). An increase of about 3- to 4-fold
in the expression of endocrine FGF15, the mouse counter-
part of human FGF19, in the ileum was also observed in
the FGFR4−/− mice (Figure 6C). Hepatic FGF21 is the
major eFGF that activates FGFR1-KLB in adipocytes, and
ileal FGF15/19 is the primary source of the factor that acti-
vates FGFR4-KLB in hepatocytes and secondarily FGFR1-
KLB in adipocytes.
Changes in expression of genes involved in breast tissue
metabolism
Circulating FGF21 and enterohepatic FGF19 are potent
systemic metabolic regulators, and at elevated levels in
response to stress, they normalize local and systemic
metabolic parameters by targeting the adipose tissue and
liver through FGFR1 and FGFR4, respectively, in partner-
ship with KLB [10,17,18,52]. We showed by analysis of
early gene responses to FGF21 that FGF21 also impacts
the breast fat tissue directly [17], owing to the expression
of KLB in adipose compartment together with FGFR1
(Figure 5A, 5B, Additional file 1: Figure S1A, S1C). Recent
analyses using our adipocyte-specific FGFR1-deficient
mice along with KLB-deficient mice [13,18,20] has made it
clear that the adipocyte FGFR1-KLB complex specificallymediates the great majority of systemic metabolic as well
as anti-obesogenic and anti-diabetic effects of FGF21. This
indicates that the adipocyte is the specific target of endo-
crine FGF21, which underlies its therapeutic activities
against obesity and diabetes that are also risk factors for
some cancers. Although hepatocytes are the primary tar-
get of FGF15/19, the endocrine factor may also act on the
FGFR1-KLB partnership in adipocytes similar to FGF21.
FGFR4 is not expressed in the breast that is comprised
mostly of adipocytes (fat) and its deficiency elevates both
FGF21 and FGF15/19 and other adipokines (Figures 5A,
5B and 6). Thus the mechanisms underlying the delay of
TGFα-driven breast cancer development by the FGFR4
deficit may be related to metabolic activities of FGF21/19
that cause systemic metabolic programming that in turn
impacts local metabolic, and therefore, cellular effects
such as the decrease in mitoses (Figure 4). We thus pro-
ceeded to perform analyses of the effect of the FGFR4 de-
ficiency on expression of major regulatory and enzyme
genes involved in the pathways of adipogenesis, fatty acid
metabolism, glucose metabolism and mitochondrial func-
tion in normal breast and breast tumor.
An increased expression of adiponectin (ADIPOQ) in
breast tissues in all FGFR4-ablated mice mirrored that
in the circulation (Figure 6D, 6A). Even in tumor foci
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100-fold, ADIPOQ was increased 11-fold by FGFR4 defi-
ciency (Figure 6D). Expression of adiponectin receptor 1
(AdipoR1) was as high as FGFR1 and increased in tu-
mors hosted in the FGFR4-deficient mice (Figure 5A).
Other diverse genes exhibiting either up- or down-
regulation consistently across age-matched (8 months)
pairs of WT and KO, and Tg and KO-Tg tissues, were
summarized according to those potentially contributing
to the delay of breast tumorigenesis by FGFR4 defi-
ciency. We predict that these changes may be the major
contribution and/or consequence of the FGFR4 defi-
ciency and the related elevation in the systemic FGF21
and FGF19 in mammary tumorigenesis.
Adipose tissue is not only the fat energy repository, but
also a dynamic endocrine organ important for hormone
and adipokine secretion that mediates cross-talk between
adipocytes and multiple organs [50,53,54] (Figure 6A).
Adipose tissue dysfunction contributes to obesity and
metabolic syndrome, which are risk factors for breast can-
cer [21,22,24]. Analyses of expression of 84 key genes in-
volved in adipogenesis and adipocyte functions in the
breast and mammary tumor tissues from WTand KO, and
from Tg and Tg-KO indicated that the FGFR4 deficiency
impacts the adipogenesis and adipocyte functions related
to adipokine secretion and lipid metabolism in both breast
and breast tumor tissues. FGFR4 ablation in general across
each group decreased the expression of Srebp1, Cebp
delta, Dlk1, Klf2, Irs2, E2F, CDK4, CCND1, Jun, Src and
Wnt5b, while increased the expression of adiponectin,
adipsin, HSL, PPAR alpha, Cdkn1a, Fabp4 (aP2) and UCP1
(Table 2). These changes have been implicated in growth,
differentiation and maintenance of adipocytes and thus may
perform the same functions in the breast adipose tissue
compartment and modulation of lipolysis and lipogenesis
in the breast. These may also indirectly affect development
of breast tumor cells in the breast microenvironment. Not-
ably, some of the changes were related to inhibition of cell
proliferation. The increases in adiponectin and adipsin, and
changes of systemic levels of other adipokines further indi-
cate the changes of secretory function of the adipose com-
ponent in the breast, which may impact breast epithelial
tumors expressing adipokine receptors such as AdipoR1 at
an early stage of development.
The FGFR4 deficiency causes mildly elevated levels of
systemic lipids accompanied by a mild obese phenotype
[36]. Alterations in the expression of genes involved in
fatty acid and lipid metabolism are associated with meta-
bolic syndrome or metabolic disorders. They are also
risk factors for multiple diseases, including obesity and
diabetes as well as cancer [55,56]. Aberrant oxidation
of fatty acids generates reactive oxygen species (ROS)
that cause cell damage and tissue inflammatory re-
sponse. Analyses of 84 key genes and other componentsinvolved in the regulation and enzymatic pathways of
fatty acid and triacylglyceride metabolism revealed the
upregulation of Acly, Acot3, Acsl5, Acsm3, Cpt1b, Cpt2,
Fabp4, Gyk, Gpd2, HSD17B4, Lipe and Slc27a4, and
downregulation of Acox2, Fabp5 and Slc27a5 (Table 3)
due to FGFR4 deficiency across the breast and tumor
tissues in each group. Acot3, Acox2 and HSD17B4 are
peroxisomal enzymes, Acsl5 and Acsm3 are mitochon-
drial enzymes, and Slc27a4 and Slc27a5 are ER-localized
enzymes involved in the metabolism (oxidation and
synthesis) of medium-chain, and long-chain to very-
long-chain fatty acids, including cholesterol/bile acids.
Slc27a5 is involved in both bile acids and very-long-
chain fatty acid synthesis. Cpt1b and Cpt2 are members
of the carnitine O-palmitoyltransferase family involved
in the net transport of long-chain fatty acyl-CoAs from
the cytoplasm into the mitochondria for beta-oxidation.
Fabp4 binds both long-chain fatty acids and retinoic acid
and delivers them to their cognate receptors in the nu-
cleus, such as PPARs. Mitochondrial Gyk and Gpd2 are
key enzymes in the regulation of glycerol uptake and
metabolism. These results indicate that the FGFR4 defi-
ciency in large part alters fatty acid and lipid catabolism
and energy metabolism primarily in mitochondria, per-
oxisomes and the ER in breast tissues. Some of these
changes have been reported as contributing factors in
the pathology of not only obesity and associated diabetes
but also cancer.
The genome-wide FGFR4 deficiency causes moderate,
but significant changes in glucose and insulin sensitivity.
Changes in glucose metabolism are common in cancer
progression that most often exhibits increased aerobic
glycolysis and decreased oxidative phosphorylation even
in the presence of sufficient oxygen to actively supply
both energy and substrates of biosynthesis [57,58]. We
further analyzed 84 key genes involved in the regulation
and enzymatic pathways of glucose metabolism in the
breast and breast tumor tissues. Our analyses revealed
the upregulation of fructose-1,6-bisphosphatase (Fbp)2,
phosphoenolpyruvate carboxykinase (Pck)1, pyruvate
dehydrogenase kinase (Pdk)4 and glycogen synthetase
(Gys)2, and downregulation of 2-phospho-D-glycerate
hydrolyase (Eno)3, phosphoglycerate mutase (Pgam)2,
mitochondrial glucokinase (Gck or HK4), the catalytic
subunit of glucose-6-phosphatase (G6pc) and glycogen
phosphorylase (Pygm) (Table 4). Fbp2 is a regulatory en-
zyme in gluconeogenesis that catalyzes the hydrolysis of
fructose 1,6-bisphosphate to fructose 6-phosphate. Pck1,
also called PEPCK1, is the main control point in gluconeo-
genesis by catalyzing the formation of phosphoenolpyr-
uvate from oxaloacetate. PDK4 inhibits the mitochondrial
pyruvate dehydrogenase complex, therefore decreases the
oxidation of pyruvate in mitochondria to acetyl-CoA.
Gys2 is the rate-limiting step in the synthesis of glycogen.
Table 2 Effects of FGFR4 deficiency on adipogenesis, adipose secretory function and metabolic pathways in breasts
and breast tumor
Proteins WT KO Tg KO-Tg
1. Adipokines and adipose enzymes:
Adiponectin 1 1.64 (0.23)* 0.01 (0.002) 0.11 (0.02)
Adipsin 1 3.32 (0.17) 0.12 (0.03) 0.43 (0.06)
Leptin 1 0.55 (0.04) 0.003 (0.0001) 0.05 (0.004)
Lipoprotein lipase 1 0.92 (0.17) 0.08 (0.02) 0.25 (0.06)
Hormone sensitive lipase 1 2.02 (0.31) 0.11 (0.02) 0.31 (0.03)
2. PPAR gamma targets:
Fabp4 1 1.62 (0.26) 0.04 (0.01) 0.15 (0.03)
FASN 1 1.01 (0.23) 0.14 (0.03) 0.35 (0.04)
IRS2 1 0.12 (0.03) 1.84 (0.35) 0.27 (0.08)
Glut4 1 0.66 (0.12) 0.05 (0.003) 0.18 (0.04)
SREBP1 1 0.27 (0.06) 1.97 (0.29) 0.33 (0.04)
3. Adipogenesis regulation:
(1) Pro-adipogenesis
Cyclin D1 1 0.46 (0.10) 6.61 (0.29) 3.42 (0.18)
Cdk4 1 0.43 (0.08) 5.14 (0.37) 2.23 (0.19)
Cebpd 1 0.24 (0.05) 7.26 (0.48) 2.46 (0.15)
E2F1 1 0.23 (0.03) 2.16 (0.36) 0.71 (0.11)
Jun 1 0.56 (0.08) 2.93 (0.26) 1.52 (0.30)
Sfrp5 1 0.55 (0.10) 0.01 (0.002) 0.04 (0.005)
Src 1 0.19 (0.03) 4.72 (0.51) 2.31 (0.38)
Wnt5b 1 0.35 (0.06) 3.01 (0.23) 1.37 (0.29)
(2) Anti-adipogenesis
Cdkn1a (p21) 1 1.65 (0.18) 2.44 (0.14) 3.71 (0.26)
Dlk1 1 0.31 (0.04) 1.03 (0.13) 0.12 (0.03)
Klf2 1 0.007 (0.001) 1.23 (0.16) 0.004 (0.0005)
(3) Others
Ppara 1 7.33 (0.47) 0.31 (0.05) 1.36 (0.17)
Ucp1 1 177.1 (1.57) 0.12 (0.02) 9.94 (1.03)
*mRNA levels were normalized to β-actin levels in the respective samples and then expressed as fold changes relative to that of the wild-type (WT) breasts, which
is assigned as an arbitrary unit of 1. Data are mean (SD): P <0.05 (n = 4 for each group). FGFR, fibroblast growth factor receptor; KO, FGFR4 knockout mice; Tg,
MMTV-TGFα transgenic mice; KO-Tg, FGFR4−/−: MMTV-TGFα bigenic mice.
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phosphoenolpyruvic acid in the glycolytic pathway. Pgam2
catalyzes the reversible reaction of 3-phosphoglycerate to
2-phosphoglycerate in the glycolytic pathway. Gck phos-
phorylates glucose to produce glucose-6-phosphate as the
first step in the glucose metabolic pathway. G6pc hydro-
lyzes glucose-6-phosphate to glucose in the ER. Pygm is
an enzyme involved in glycogenolysis. The changes in
these genes observed in the FGFR4 deficient breast tissues
cluster around those associated with negative effects on
glycolysis and glucose oxidation as well as promotion of
glucose storage. These collective changes are also gener-
ally consistent with the delay of tumorigenesis.As some of the genes in the forgoing analyses were re-
lated to mitochondrial energy metabolism, we further
analyzed 84 key and related genes involved in the bio-
genesis and function of mitochondria. Tumor cells often
exhibit mitochondrial dysfunction that is associated with
increased glycolysis, oxidative stress and ROS damage.
Deregulation of these processes is a major patho-
logical factor in metabolic syndrome, obesity and cancer
progression [59-61]. In addition to some of those de-
scribed above, we consistently found the upregulation of
Cpt1b and mitochondrial uncoupling protein (UCP)1 as
well as mitofusin (Mfn)2, and downregulation of NAMPT,
Slc25a5 and Slc25a21 (Table 5). UCP1 (Slc25a7) separates
Table 3 Effects of FGFR4 deficiency on fatty acid metabolic pathways in breasts and breast tumor
Proteins WT KO Tg KO-Tg
1. Fatty acid metabolism
Acot3 1 3.63 (0.23)* 1.41 (0.11) 7.92 (0.44)
Acsl4 1 1.25 (0.17) 26.51 (1.47) 52.33 (3.74)
Acsl5 1 6.52 (0.51) 1.36 (0.14) 5.27 (0.48)
Acsm3 1 16.45 (0.77) 0.87 (0.09) 5.16 (0.42)
Aldh2 1 2.14 (0.13) 2.72 (0.26) 8.03 (0.58)
Acly 1 3.43 (0.37) 1.64 (0.25) 4.32 (0.31)
Acox2 1 0.46 (0.08) 24.76 (0.87) 11.16 (0.58)
HSD17B4 1 1.88 (0.33) 1.62 (0.24) 3.45 (0.41)
2. Fatty acid transport
Cpt1b 1 6.92 (0.71) 0.13 (0.02) 0. 72 (0.14)
Cpt2 1 2.82 (0.17) 0.63 (0.09) 3.64 (0.24)
Fabp4 1 1.53 (0.31) 0.05 (0.01) 0.26 (0.02)
Fabp5 1 0.02 (0.003) 0.61 (0.05) 0.04 (0.01)
Slc27a4 1 1.91 (0.35) 0.28 (0.04) 0.64 (0.08)
Slc27a5 1 0.16 (0.04) 2.31 (0.19) 0.74 (0.12)
3. Triacylglycerol Metabolism
GyK 1 3.97 (0.28) 10.34 (0.72) 33.59 (0.65)
Gpd2 1 9.92 (0.56) 0.96 (0.22) 4.03 (0.35)
Lipe 1 2.30 (0.15) 0.16 (0.03) 0.43 (0.12)
Lpl 1 0.9 (0.17) 0.12 (0.02) 0.30 (0.03)
*Data are mean (SD): p <0.05 (n = 4 for each group). FGFR, fibroblast growth factor receptor; KO, FGFR4 knockout mice; Tg, MMTV-TGFα transgenic mice; KO-Tg,
FGFR4−/−: MMTV-TGFα bigenic mice.
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dissipated as heat. Mfn2 encodes a mitochondrial mem-
brane protein that participates in the maintenance
and operation of the mitochondrial network. It may be also
a hyperplasia suppressor and a risk gene for obesity.Table 4 Effects of FGFR4 deficiency on glucose metabolic
pathways in breasts and breast tumor
Proteins WT KO Tg KO-Tg
1. Glucose metabolism:
Eno3 1 0.18 (0.04) * 0.10 (0.02) 0.03 (0.002)
Pgam2 1 0.22 (0.03) 0.11 (0.02) 0.05 (0.01)
Gck 1 0.45 (0.07) 0.41 (0.07) 0.07 (0.02)
Fbp2 1 2.23 (0.37) 0.07 (0.01) 0.55 (0.04)
G6pc 1 0.04 (0.003) 1.43 (0.11) 0.13 (0.03)
Pck1 1 3.39 (0.44) 0.01 (0.001) 0.12 (0.02)
Pdk4 1 6.86 (0.57) 0.15 (0.03) 1.02 (0.14)
2. Glycogen metabolism
Gys2 1 2.79 (0.19) 0.02 (0.003) 0.12 (0.03)
Pygm 1 0.22 (0.03) 0.08 (0.01) 0.04 (0.002)
*Data are mean (SD): p <0.05 (n = 4 for each group). FGFR, fibroblast growth
factor receptor; KO, FGFR4 knockout mice; Tg, MMTV-TGFα transgenic mice;
KO-Tg, FGFR4−/−: MMTV-TGFα bigenic mice.NAMPT is the rate-limiting enzyme in the mammalian
nicotinamide adenine dinucleotide biosynthesis (NAD) sal-
vage pathway. It is overexpressed in multiple cancers, and
inhibition of NAMPT significantly suppresses tumor cell
growth. Slc25a5, adenine nucleotide translocator 2 (Ant2),
catalyzes the exchange of cytoplasmic ADP with mito-
chondrial ATP across the mitochondrial inner membrane.
Suppressed expression of this gene has been shown toTable 5 Effects of FGFR4 deficiency on mitochondrial
biogenesis and energy metabolism in breasts and breast
tumor
Proteins WT KO Tg KO-Tg
Cpt1b 1 6.92 (0.24)* 0.13 (0.02) 0.72 (0.04)
Mfn2 1 1.92 (0.34) 0.26 (0.03 0.49 (0.03)
NAMPT 1 0.22 (0.01) 7.64 (0.65) 2.33 (0.37)
Slc25a5 1 0.44 (0.16) 3.92 (0.43) 1.67 (0.23)
Slc25a21 1 0.31 (0.05) 0.60 (0.04) 0.09 (0.02)
Slc25a24 1 0.57 (0.07) 4.14 (0.29) 1.91 (0.13)
Ucp1 1 170.5 (1.57) 0.17 (0.02) 8.54 (0.45)
*Data are mean (SD): p <0.05 (n = 4 for each group). FGFR, fibroblast growth
factor receptor; KO, FGFR4 knockout mice; Tg, MMTV-TGFα transgenic mice;
KO-Tg, FGFR4−/−: MMTV-TGFα bigenic mice.
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2-oxodicarboxylate carrier, transports C5-C7 oxodicar-
boxylates across the inner membranes of mitochondria
including 2-oxoadipate, 2-oxoglutarate, adipate and glu-
tarate, which are common intermediates in the catabol-
ism of lysine, tryptophan and hydroxylysine in mammals.
Slc25a24 is another Ca2+-dependent mitochondrial car-
rier protein for ATP-Mg/Pi. Overall, the changes in ex-
pression of these genes appear to be largely related to
mitochondrial biogenesis, energy production and homeo-
stasis. Consistent with the tumor-delaying effect of the
FGFR4 deficiency, some of these changes largely have
been associated with tumor development.
Changes in the expression of inflammatory factors
Several metabolic genes described above that exhibited
changes due to the FGFR4 deficiency are also associated
with the response of peroxisomes-ER-mitochondria sys-
tem upon metabolic alterations and stress. This is con-
sistent with a large number of observed cystic breast
tumors as well as an increased rate of foot cyst and seba-
ceous gland hyperplasia triggered by the FGFR4 defi-
ciency. This indicates a possible inflammatory response
contributing to these types of abnormalities. We thus
selectively analyzed the changes of IFNγ, TNFα and
IL-6 across each of the WT and KO, and the Tg and
KO-Tg groups (Figure 7). FGFR4 ablation led to in-
creases of IFNγ, TNFα and IL-6 more than 3.5-, 5.0-
and 4.0-fold, respectively (Figure 7A, 7B and 7C). The
overexpression of TGFα also led to increases of TNFα
and IL-6 (Figure 7B and 7C). The combination of FGFR4Figure 7 Upregulation of some inflammatory genes due to
fibroblast growth factor receptor (FGFR)4 deficiency. Changes in
expression of IFNγ (A), TNFα (B), IL-6 (C) and Cyclooxygenase (Cox)2
(D) in the breast and breast tumor tissues from wild-type (WT),
FGFR4 knockout (KO), MMTV-TGFα transgenic (Tg) and FGFR4−/−:
MMTV-TGFα bigenic (KO-Tg) mice at 6 months were determined by
quantitative PCR. mRNA levels were normalized to β-actin levels in
the respective samples and then expressed as fold changes relative
to that of the WT breast, which is assigned as an arbitrary unit of 1.
Data are means ± SD; P <0.05 (n = 4 for each group).deficiency and TGFα overexpression further increased
expression levels that were particularly notable in the
case of IL-6 (Figure 7C). In contrast, the FGFR4 defi-
ciency decreased the expression of Cyclooxygenase (Cox)
2 (Figure 7D).
Inhibition of mammary tumor cells by targeting NAMPT
We observed in metabolic pathways by quantitative PCR
analyses that NAMPT is overexpressed in breast tumor
tissue and FGFR4 deficiency downregulates the expres-
sion. To determine whether this occurs in tumor foci, we
performed IHC analyses on tissue sections from mice and
human patients. Results indicate that mouse NAMPT is
highly expressed in the luminal epithelium-derived tumor
cells with highly expanded tubular, adenoid cystic and
papillary tumor tissue structures (Figure 8A, orange stain-
ing), and that FGFR4 deficiency attenuates the NAMPT
levels (Figure 8B, 8C). The cytosolic staining was also uni-
formly high in the tumor foci from 87% of 48 breast can-
cer patients analyzed (Figure 8D), but was weak in the
matched phenotypically normal breast tissues and the
adipose and stromal tissues surrounding tumor nodules
(Figure 8D, 8E).
Our results indicate that NAMPT may be a down-
stream target for further reduction of breast tumorigen-
esis. We used a catalytic inhibitor of NAMPT, FK866,
which was shown to deplete energy reserve in metabol-
ically active tumor cells and induce tumor cell death, to
treat the isolated tumor cells from solid tumor nodes.
FK866 at 5 μM led to significant inhibition of cell popu-
lation growth (Figure 8F). On day 5 of treatment, FK866
reduced the cell populations to 13 and 10% in the Tg and
KO-Tg groups, respectively, of the untreated cells. As a
comparison, a highly cytotoxic compound extracted from
Tripterygium, Triptolide, also exhibited potent suppressive
effect (Figure 8F, Additional file 1: Figure S3A-S3C).
Tumor sphere formation in a serum-free condition is indi-
cative of ability of single primary tumor cells to clonally ex-
pand and repopulate tumors. Isolated primary tumor cells
exhibited 0.47 and 0.25% efficiency from 3,000 cells/well in
a cell-culture well with a culture surface of 10 cm2 from
the Tg and KO-Tg tumors, respectively, in forming visible
tumor spheres (Additional file 1: Figure S3D, S3E); the
presence of 5 μM FK866 blocked formation of the tumor
sphere (not shown).
Discussion
Alterations in local and systemic glucose, lipid and en-
ergy metabolism and mitochondrial function are often
associated with progression of multiple types of cancer,
including breast cancer [21,24,55-57,59,62]. In this re-
port, we evaluated the local and systemic metabolic
effects resulting from a germline deficiency of metabolic
regulator FGFR4 [30] on breast cancer development
Figure 8 Inhibition of mammary tumor cell growth by targeting nicotinamide phosphoribosyltransferase (NAMPT). Tissue sections from
mouse breast tumor nodes in MMTV-TGFα transgenic (Tg) mice (A), FGFR4−/−: MMTV-TGFα bigenic (KO-Tg) mice (B) and normal breast (C), or
from human breast tumor (D) and matched normal breast (E) were analyzed for NAMPT expression (blue arrow, orange staining) by IHC, examined
under microscope and representative sections were shown. Tumor cells were isolated from established solid tumor foci in Tg and KO-Tg mice,
cultured for one day and then treated with vesicle dimethyl sulfoxide (DMSO), 5 μM FK866 or 5 μM Triptolide for 5 days. Treatment with
FK866, a catalytic inhibitor for NAMPT, significantly reduced the population growth of primary tumor cells (F). Light blue line: vesicle DMSO;
green line: 5 μM FK866; black line: 5 μM Triptolide as positive control; Filled shapes (square, triangle and circle): tumor cells from Tg mice; open
shapes: tumor cells from KO-Tg mice.
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function of the WT FGFR4 tyrosine kinase is metabolic
regulation in the liver where it is highly expressed
[30,37]. It is, however, expressed at negligible levels in
breast [38]. In contrast to other receptor tyrosine kinases
with growth-promoting effects involved in tissue and cel-
lular structure development, adult damage repair and
tumorigenesis, such as FGFR1 [1,2,6,63], overexpression,
or deletion of FGFR4 caused no defects in embryonic de-
velopment and adult tissue and cellular homeostasis be-
yond metabolic homeostasis [30,36,39]. In particular,
there were no detectable effects on mammary cellular
and tissue structure, lactation, birth rate and survival of
offspring beyond tumorigenesis caused by overexpression
of transgenic TGFα. Even though FGFR4 is not at play in
breast cells in general, we have shown that it affected sys-
temic metabolic parameters and factors that impact the
breast through the non-canonical metabolic functions
of eFGF. Notably, deficiency of FGFR4 significantly
upregulated hepatic and systemic FGF21, which is a
stress-induced hormone mediating communication with
adipocytes via FGFR1-KLB to trigger adipocyte signals
and metabolites that in turn impact liver and other tis-
sues [13,50]. Breast is comprised of mostly adipose tissue,
which is responsive to changes in systemic metabolism.
The adipose compartment creates a microenvironment
symbiotic with breast epithelial cells in ducts and lobuleswith large impact on functions and pathology including
development of breast tumors. Similar to adipocytes in
peripheral fat depots, KLB and FGFR1 are co-expressed
in the fat in breast (Figure 5, Additional file 1: Figure S1),
which enables the response of breast to FGF21 and
potentially other factors that target adipocytes [17].
The metabolic alterations and upregulation of FGF21
by loss of FGFR4, the fatty nature of breast and the
lack of mammary expression of FGFR4 thus underlie the
model used in this study for evaluating the systemic and
microenvironmental metabolic effects on breast epithelial
carcinogenesis.
Indeed, by combining TGFα overexpression in breast
epithelial cells and the FGFR4 deficiency outside the
breast, we found that ablation of FGFR4 reduced TGFα-
driven breast cancer incidence, delayed breast cancer
progression and improved host survival. This coincided
with reduced local tumor cell proliferation. Although the
deletion of FGFR4 had no significant effect on Her2
activity [64] stimulated by overexpression of TGFα,
the deficiency significantly elevated hepatic and sys-
temic FGF21, ileal FGF15/19 and serum adiponectin.
In contrast, several other adipokines including Fetuin A,
IGF-1, IGFBP-1, RBP4 and TIMP1 were depressed in the
FGFR4-deficient animals. The changes of these serum
adipokines and factors triggered by the FGFR4 defi-
ciency are generally consistent with the observed net
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that the effect of FGFR4 deficiency on delaying breast
cancer progression lies in the alteration of metabolic
pathways governed by eFGF signaling and other sys-
temic factors.
Adiponectin is an early response effecter in the
FGF21-KLB-FGFR1 pathway in adipocytes [18,65,66]. It
is an adipose hormone involved in the suppression of
metabolic diseases, such as obesity and non-alcoholic
fatty liver disease (NAFLD), by reducing lipogenesis and
systemic lipid levels and enhancing fatty acid oxidation
through acting on AdipoR1/2 [22,53,67,68]. It is sug-
gested to also have anti-proliferative, anti-inflammatory,
and therefore, antitumor effects associated with meta-
bolic disorders. We show here that the adiponectin re-
ceptor adipoR1 is highly expressed in both breast and
breast epithelial tumors. Thus both adiponectin of sys-
temic origin from distal fat depots and from local breast
adipocytes under the control of FGF21 could play a
major role directly on breast tumor epithelial cells and
their microenvironment. IGF-1 is a hepatic hormone and
promotes cell growth and carcinogenesis [69,70]. TIMP1,
an inhibitor of the matrix metalloproteinases (MMPs), has
also been shown to promote tumor progression in numer-
ous tissues [71]. Collectively, these specific positive and
negative alterations of local microenvironmental and sys-
temic adipokines and factors are consistent with the delay
of breast tumorigenesis.
FGF21 and FGF19 are potent regulators of glucose, lipid
and energy metabolic homeostasis and suppress obesity
and diabetes through targeting adipose tissue and liver
[14,18,20,26]. These metabolic effects occur without a
same extent of growth and proliferation-promoting activ-
ity characteristic of canonical FGFs such as FGF1 and
FGF2 [11,14]. We confirmed our prediction that the breast
adipose compartment is also a target of systemic FGF21
[17]. The upregulation of Cpt1, Pck1, PPARα and Ucp1
in addition to adiponectin in breast tissue is consistent
with previous studies in the independent adipose tissue
and adipocytes, which showed that FGF21 activates the
adipose FGFR1-KLB complex leading to significant changes
in the expression of these metabolic genes and regulators
[18,72]. Therefore, these results support the notion that
FGF21 and possibly FGF19/15 as well, are top candi-
dates underlying changes in metabolic pathways and
concurrent delay of breast cancer development observed
here (Figure 9). They not only modulate metabolic path-
ways in peripheral fat depots that affect the breast system-
ically, but also directly act on breast adipocytes with major
microenvironmental impact on mammary epithelial cells
during development of mammary tumor. These activities
of FGF21 and possibly FGF19 on adipocytes that elicit
tumor suppressive metabolic signals appear sufficient to
override tumor-promoting effects of elevated bile acids,inflammation and mild metabolic abnormalities elicited by
the FGFR4 deficiency.
Consistently, we further showed the downregulation
of several cell proliferation-promoting genes such as
CCND1, CDK4, E2F, Jun, NAMPT, Src and Wnt5b and
inflammatory Cox2, and upregulation of proliferation-
inhibitory genes such as Cdkn1a and Mfn2. These
changes are likely not limited to only adipose tissue and
adipogenesis. They are in line with the upregulation of
adiponectin and downregulation of systemic factors such
as IGF-1 and TIMP1 that otherwise promote cell prolif-
eration. NAMPT as a downstream target of FGFR4 defi-
ciency and FGF21 elevation is highly expressed in breast
tumor foci but attenuated by the FGFR4 deficiency. In-
hibition of NAMPT by FK866 suppressed the growth of
isolated tumor cells from both Tg and KO-Tg mice and
the formation of tumor spheres from single tumor cells,
an indicator of the presence of cells with the ability
to expand and repopulate tumors (Figure 8, Additional
file 1: Figure S3). This is consistent with other studies in
many other types of cancer [73,74], in which NAMPT is
overexpressed or mutated. Downregulation or blockade
of the NAD+ generation led to cessation of cell prolifera-
tion or apoptotic cell death. Enhanced NAMPT activity
insures a constant energetic growth capacity and malig-
nant behavior by constantly replenishing the NAD+ pool
that critically links glycolysis, the tricarboxylic acid
(TCA) cycle, oxidative phosphorylation, ATP flux, in-
flammation and redox regulation.
Furthermore, we found the upregulation of Acot3,
Acsl5, Acsm3, HSD17B4, HSL and CPT1/2 that indicate
reduced lipogenesis or enhanced lipolysis and fatty acid
oxidation. Upregulation of Acly, Fbp2, Gys2, Pck1 and
Pdk4 and downregulation of Eno3, Pgam2, Gck and
Pygm indicate an inhibition of glycolysis, the hallmark of
tumorigenesis [57,58,75,76]. Acsl5, Acsm3, Cpt1/2,
Gpd2, Mfn2, Slc25a5, Slc25a21, Slc25a24 and Ucp1 are
localized in mitochondria. Changes of these mitochon-
drial genes are consistent with changes in fatty acid and
lipid catabolism and with changes of enzymes localized
in the peroxisomes and ER. Defects in biogenesis, glu-
cose/fatty acid oxidation and energy production of mito-
chondria lead to changes in glycolysis, oxidative stress
and ROS damage that are factors common to obesity
and tumorigenesis [21,23,24,55,59,61,77,78]. Changes of
these metabolic enzymes and regulators are consistent
with systemic elevation and anti-obesogenic functions of
FGF21 and FGF19 that translate into a delay of breast
tumorigenesis.
We showed previously that FGF21 is induced in the liver
by diverse transcriptional regulators in response to a wide
range of stress conditions that include obesity, fatty liver
disease and carcinogenesis [13,50]. Hepatic FGF21 con-
trols the hepatocyte to adipocyte communication arm of
Figure 9 Possible mechanisms of inhibition of mammary tumorigenesis by fibroblast growth factor receptor (FGFR)4 deficiency.
Deficiency of hepatic metabolic regulator FGFR4 has little effect on breast cellularity and function where FGFR4 is not at play. The deficiency
causes systemic metabolic changes and constitutive elevation of expression of systemic FGF21 which is normally elevated only during diverse
hepatic stress conditions that are disease-suppressive. FGF21 specifically acts on adipocytes both in fat depots and breast. Both circulating and
breast microenvironmental secretory products from adipocytes affect cellular and metabolic behavior of breast epithelial cells. Systemic changes
in metabolism governed by hepatocyte FGFR4-betaKlotho (KLB) and both systemic and microenvironmental changes governed by adipocyte
FGFR1-KLB impact breast parenchymal cell behavior and tumor progression. A +M: adipokines and metabolic effects.
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lenges through restoring metabolic homeostasis [13,50].
Based on our current results, breast is also within this
communication axis. Moreover, since breast is essentially
an adipose organ, its non-adipocyte components are also
the recipients of this axis within the local breast tissue
microenvironment. The effects of the FGFR4 deficiency
on breast tumors are most likely through these systemic
indirect metabolic effects that modify the local adipose tis-
sue microenvironment and epithelial compartment in
breast duct and lobular structures and the developing ma-
lignant cells. These indirect effects are likely mediated in
large part by elevated FGF21 and FGF19, which regulate
pathways related to adipogenesis and adipose function,
lipid and glucose metabolism, peroxisomal and ER meta-
bolic stress, and mitochondrial function and energy me-
tabolism as reported here and by others [14,18]. We
therefore propose that in respect to breast, this hepatic-
breast adipose communication axis may have evolved as
an overall tumor suppressive influence in the local breast
microenvironment. This is likely interwoven with the
benefit of the general axis to the organism through nor-
malizing and reprogramming metabolic parameters and
pathways during stress conditions, in particular tumori-
genic metabolic stress (Figure 9).
This study extends our discovery that hepatic FGFR4
signaling underlies control of cholesterol to bile acid me-
tabolism by showing the local and systemic effects on
tumor development in a tissue where FGFR4 is normally
not directly at play. The corollary of the tumor-
suppressive effects of the FGFR4 deficiency in the breast
is that chronic activity of hepatic FGFR4 and its systemic
endocrine effects may contribute to promotion of breast
tumors via the inverse of the changes in systemic adipo-
kines and factors and local metabolic reprogramming we
reported here. Our study implicates for the first time
a potential microenvironmental metabolic role of the
adipocyte compartment in breast tumor progression inresponse to eFGF/FGFR signaling. The notable rise in
FGF21 that is specific for adipocyte FGFR1-KLB and
correlates with the delay in breast tumor progression sug-
gests that FGF21 and its agonists may be of similar benefit
for control of breast tumor progression, as they are for al-
leviation of obesity and diabetes via the adipocyte com-
partment. Furthermore, our study provided potential new
targets, such as FGF21, adiponectin, NAMPT and Acly,
for suppressing breast tumor malignancy concurrently
with inhibition of FGFR.
Conclusions
Here we showed that systemic and local metabolic alter-
ations caused by a deficiency of the metabolic regulator
FGFR4 reduce TGFα-induced tumor incidence and pro-
gression in breasts where FGFR4 expression is negligible.
The FGFR4 deficiency causes increases in systemic factors,
including the adipocyte-targeting hepatic stress hormone
FGF21 and ileal FGF15 (human FGF19), accompanied by
increases in the tumor-suppressive adipokine adiponectin
and decreases in tumor-promoting adipokines IGF-1 and
TIMP1 that are controlled by anti-obesogenic FGF21.
Changes in major metabolic pathways related to adipocyte
function, lipid and glucose metabolism and mitochondrial
function within the breast and tumor tissues are coincident
with the delay of mammary tumorigenesis. They suggest
novel roles of FGF21 signaling and metabolic reprogram-
ming in suppressing mammary tumors that rise from lu-
minal epithelial cells in the ducts and lobules surrounded
mostly by FGF21-responsive adipocytes. Our results pro-
vide new insights into the impact of microenvironmental
and systemic metabolic reprogramming by endocrine FGF
signaling on tumorigenesis in the breast where adipocytes
are a major symbiotic component.
ADIPOQ: adiponectin; AdipoR1: adiponectin receptor
1; BrdU: 5-Bromo-2′-deoxyuridine; BSA: bovine serum al-
bumin; Cox2: cyclooxygenase-2; DCIS: ductal carcinomas
in situ; DMEM: Dulbecco’s modified Eagle’s medium;
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mal growth factor receptor; Eno3: 2-phospho-D-glycerate
hydrolyase; Fbp2: fructose-1,6-bisphosphatase 2; FGFR:
fibroblast growth factor receptor; FGF21: fibroblast
growth factor-21; G6pc: catalytic subunit of glucose-6-
phosphatase; Gck: mitochondrial glucokinase HK4; Gys2:
glycogen synthetase; Her2; human epidermal growth fac-
tor receptor-2; H&E: hematoxylin and eosin; HS: heparan
sulphate; hUDH: high-grade usual duct hyperplasia; IFN:
interferon: IGF1: insulin-like growth factor-1; IL6: inter-
leukin 6; IHC: immunohistochemistry; IPITT: intraperito-
neal insulin tolerance test; KL: Klotho; KLB: betaKlotho;
KO: FGFR4 knockout C57BL/6 J mice; KO-Tg: FGFR4−/−:
MMTV-TGFα bigenic mice; LCIS: lobular carcinomas
in situ; Mfn2: mitofusin 2; NAMPT: nicotinamide phos-
phoribosyltransferase; OGTT: oral glucose tolerance test;
PBS: phosphate-buffered saline; Pck1: phosphoenolpyr-
uvate carboxykinase 1 (PEPCK); PCR: polymerase chain
reaction; Pdk4: pyruvate dehydrogenase kinase 4; Pgam2:
phosphoglycerate mutase-2; Pygm: glycogen phosphoryl-
ase; RBP4: retinol binding protein-4; ROS: reactive oxygen
species; TIMP1: tissue inhibitor of metalloproteinase-1;
Tg: MMTV-TGFα transgenic mouse; TGFα: transforming
growth factor α; TNF: tumor necrosis factor; UCP1: mito-
chondrial uncoupling protein 1; UDH: usual duct hyper-
plasia; WT: wild-type.
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